Assessing the state of Medicaid coverage for gene and cell therapies

Affiliations

¹ Sarepta Therapeutics, Inc., Cambridge, MA, USA.
² Akouos, Inc., Boston, MA, USA.
³ Spark Therapeutics, Inc., Philidelphia, PA, USA.
⁴ American Society of Gene & Cell Therapy, Waukesha, WI, USA. Electronic address: cmayer@asgct.org.

Diane Berry et al. Mol Ther. 2022.

. 2022 Sep 7;30(9):2879-2880.

doi: 10.1016/j.ymthe.2022.08.009. Epub 2022 Aug 26.

¹ Sarepta Therapeutics, Inc., Cambridge, MA, USA.
² Akouos, Inc., Boston, MA, USA.
³ Spark Therapeutics, Inc., Philidelphia, PA, USA.
⁴ American Society of Gene & Cell Therapy, Waukesha, WI, USA. Electronic address: cmayer@asgct.org.

No abstract available

Conflict of interest statement

Declaration of interests The content of this article represents the authors’ opinions and may not necessarily represent the views of their employers.

1. American Society for Gene and Cell Therapy Spinal muscular atrophy. 2021. https://patienteducation.asgct.org/disease-treatments/sma
1. Mass. Eye and Ear Communications Making gene therapy history [Poster presentation] 2019. https://focus.masseyeandear.org/making-gene-therapy-history
1. Kaiser Family Foundation . 2020. Health Insurance Coverage of Children 0-18.https://www.kff.org/other/state-indicator/children-0-18/
1. MACPAC more than half (61.1 percent) of [Medicaid’s] 73 million beneficiaries identify as Black, Hispanic, Asian American, or another non-white race or ethnicity. 2021. FactSheet: Racial and ethnic disparities in Medicaid: An annotated bibliography https://www.macpac.gov/wp-content/uploads/2021/04/Racial-and-Ethnic-Disp....
1. Shupe L., Udeze C. An analysis of healthcare plan CAR T cell coverage criteria for Medicaid beneficiaries. 2019. https://pharmafellows.rutgers.edu/wp-content/uploads/2020/08/2019-an-ana...